Sponsored Links
| AVEO's Ficlatuzumab In Combination With Gefinitib Well Tolerated In Patients With Non-Small Cell Lung Cancer; Phase 1b Data Presented At ASCO |
 |
 |
 |
| Medical News - Lung Cancer | |||
|
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced results from the Phase 1b portion of its Phase 1b/2 clinical study of ficlatuzumab in combination with gefitinib (Iressa(TM)) in Asian subjects with non-small cell lung cancer (NSCLC)... Read more: Lung Cancer News From Medical News Today
|